Technical Analysis for AGEN - Agenus Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | -2.92% | |
NR7 | Range Contraction | -2.92% | |
Narrow Range Bar | Range Contraction | -2.92% | |
Wide Bands | Range Expansion | -2.92% | |
Wide Bands | Range Expansion | -2.20% | |
Crossed Above 50 DMA | Bullish | -5.64% | |
Inside Day | Range Contraction | -5.64% | |
Wide Bands | Range Expansion | -5.64% | |
Fell Below 50 DMA | Bearish | -0.24% | |
Wide Bands | Range Expansion | -0.24% |
Alert | Time |
---|---|
Down 3% | about 2 hours ago |
Fell Below 50 DMA | about 2 hours ago |
Fell Below Previous Day's Low | about 2 hours ago |
Down 2 % | about 2 hours ago |
Down 1% | about 2 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/07/2024
Agenus Inc. Description
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Alzheimer's Disease Non Small Cell Lung Cancer Melanoma Vaccines Small Cell Lung Cancer Vaccination Carcinoma Malaria Glioma Herpes Shingles Cancer Vaccine Renal Cell Carcinoma Experimental Cancer Treatments Metastatic Melanoma Agenus Genital Herpes Treatment Of Malaria
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 42.6 |
52 Week Low | 4.775 |
Average Volume | 790,879 |
200-Day Moving Average | 16.49 |
50-Day Moving Average | 10.50 |
20-Day Moving Average | 10.24 |
10-Day Moving Average | 11.68 |
Average True Range | 1.35 |
RSI (14) | 53.27 |
ADX | 33.57 |
+DI | 25.03 |
-DI | 21.22 |
Chandelier Exit (Long, 3 ATRs) | 10.18 |
Chandelier Exit (Short, 3 ATRs) | 8.83 |
Upper Bollinger Bands | 15.68 |
Lower Bollinger Band | 4.81 |
Percent B (%b) | 0.55 |
BandWidth | 106.18 |
MACD Line | 0.40 |
MACD Signal Line | 0.41 |
MACD Histogram | -0.0097 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 11.49 | ||||
Resistance 3 (R3) | 11.50 | 11.28 | 11.37 | ||
Resistance 2 (R2) | 11.28 | 11.10 | 11.27 | 11.33 | |
Resistance 1 (R1) | 11.03 | 10.99 | 10.92 | 11.02 | 11.29 |
Pivot Point | 10.81 | 10.81 | 10.75 | 10.80 | 10.81 |
Support 1 (S1) | 10.56 | 10.63 | 10.45 | 10.54 | 10.27 |
Support 2 (S2) | 10.34 | 10.52 | 10.33 | 10.23 | |
Support 3 (S3) | 10.09 | 10.34 | 10.19 | ||
Support 4 (S4) | 10.07 |